Risk of upper gastrointestinal tract events in risedronate users switched to alendronate

Oct-10

AUTHORS : Prof Stuart Ralston, Centre for Genomic & Experimental Medicine, MRC Institute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU – Email: stuart.ralston@ed.ac.uk – Profile: https://www.ed.ac.uk/profile/stuart-ralston AND https://www.ed.ac.uk/centre-genomic-medicine/research-groups/ralston-group

JOURNAL : Calcified Tissue International

REFERENCE: 87(4):298-304

DOI : 10.1007/s00223-010-9401-0

Risk of upper gastrointestinal tract events in risedronate users switched to alendronate

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Colonic Diverticulosis and Uncomplicated Diverticulitis Are Associated With a Lower Not Higher Risk of Mortality When Confounding Factors Are Held Constant

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement